Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3655 Target Snapshot

Proto-oncogene tyrosine-protein kinase Src · SINGLE PROTEIN · Gallus gallus

399Compounds
46Assays
6Approved Drugs
389.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt P00523. Use UniProt P00523 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt P00523 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Proto-oncogene tyrosine-protein kinase Src as ChEMBL target CHEMBL3655, mapped to UniProt P00523. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Proto-oncogene tyrosine-protein kinase Src
SINGLE PROTEIN · Gallus gallus
As of 2026-09-13
ChEMBL target ID
CHEMBL3655
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P00523
Proto-oncogene tyrosine-protein kinase Src
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Proto-oncogene tyrosine-protein kinase Src is the right protein anchor across sources, using UniProt P00523 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelProto-oncogene tyrosine-protein kinase Src
UniProt AccessionP00523
Component TypeProtein
Sequence Length533 aa

Proto-oncogene tyrosine-protein kinase Src

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Proto-oncogene tyrosine-protein kinase Src, mapped to UniProt P00523. Sequence length is 533 aa.

Mapped IDP00523
Review nameProto-oncogene tyrosine-protein kinase Src
OrganismGallus gallus
Clinical Profile

Clinical Phase Distribution

6
Approved
1
Phase III
1
Phase II
1
Phase I
Assay Mix

Activity Type Distribution

IC50378.0
KD11.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5209202 9.55 Kd 0.28 Preclinical
CHEMBL5416410 9.4 IC50 0.4 Approved
CHEMBL1171837 9.05 IC50 0.9 Approved
CHEMBL285063 9.0 IC50 1.0 Preclinical
CHEMBL94061 9.0 IC50 1.0 Preclinical
CHEMBL91867 9.0 IC50 1.0 Preclinical
CHEMBL169390 9.0 IC50 1.0 Preclinical
CHEMBL598007 9.0 IC50 1.0 Preclinical
CHEMBL2403819 8.96 IC50 1.1 Preclinical
CHEMBL2403820 8.96 IC50 1.1 Preclinical
Distribution

pChEMBL Value Distribution

30
5.0
29
5.5
44
6.0
46
6.5
47
7.0
56
7.5
22
8.0
5
8.5
7
9.0
1
9.5
pChEMBL
Approved Drugs

Approved Drugs

PONATINIB
CHEMBL1171837
Approved 2012
DASATINIB
CHEMBL5416410
Approved 2006
SUNITINIB
CHEMBL535
Approved 2006
ERLOTINIB
CHEMBL553
Approved 2004
Assay Landscape

Assay Landscape

46
Total Assays
232
Tested Compounds
2
Assay Types
Binding — 43 assays, 232 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 27 197 6.8
assay format 15 35 6.9
cell-based format 1 0
Functional — 3 assays, 37 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 2 21 6.0
assay format 1 16 6.2

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine